comprehensive -WSS

comprehensive

author：explore 2025-10-02 14:38:44 - browse：4

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Bernie Sanders is gearing up to subpoena pharma CEOs

WSS

Why police arrested suspected Gilgo Beach killer away from his house

Syphilis numbers in the United States reach record heights

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Involuntary treatment for addiction doesn't work

Argenx drug significantly slows progression of nerve disorder

Philips to halt sales of sleep apnea machines in U.S.

leisure time

comprehensive

leisure time

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: The latest on Novavax, Merck, Bluebird

State Dept. review finds Biden bears some blame for Afghanistan failures

Europe sees delivery challenges ahead on Alzheimer's therapies

23andMe had bad news about my health. I wish a person had delivered it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Sports medicine is finally prioritizing gender equality

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Health Care Service Corp to buy Cigna Medicare Advantage plans

leisure time

Investment in vaccine development is lagging, report finds

Congress: Eradicate hepatitis C and reduce the deficit

Argenx drug significantly slows progression of nerve disorder

Why Medicare shouldn’t cover every FDA

Care demand spikes challenge UnitedHealth’s provider arm

Eli Lilly to acquire Versanis in heated race for weight loss drugs

knowledge

focus

focus

leisure time